Radack K L, Deck C C, Bloomfield S S
Department of Internal Medicine, University Hospital, University of Cincinnati, Ohio.
Ann Intern Med. 1987 Nov;107(5):628-35. doi: 10.7326/0003-4819-107-5-628.
To assess the effects of ibuprofen on blood pressure control in patients being treated with antihypertensive drugs.
Randomized, blinded, placebo-controlled, parallel trial of ibuprofen compared with acetaminophen and with placebo in 3-week treatment periods.
A general internal medicine clinic at a university hospital.
Forty-five patients with essential hypertension controlled by treatment with at least two antihypertensive drugs were enrolled. Of these, 41 completed the study; treatment was discontinued in 3 of the 15 patients in the ibuprofen group due to breakage of the drug capsules, and after randomization in 1 of the 14 patients in the placebo group due to unstable angina. All 15 patients in the acetaminophen group completed the study.
All previous antihypertensive regimens were continued. During the 3-week treatment, ibuprofen, 400 mg, was administered orally every 8 hours; acetaminophen, 1 g, orally every 8 hours; or placebo, 2 capsules, orally every 8 hours.
In the ibuprofen group, the mean increase from baseline after 3 weeks of treatment was significant in the average supine diastolic blood pressure (6.4 mm Hg; 95% confidence interval [CI], 1.05 to 11.75; p = 0.0239); supine mean arterial pressure (6.6 mm Hg; 95% CI, 1.25 to 11.95; p = 0.0205); and sitting mean arterial pressure (5.8 mm Hg; 95% CI, 1.57 to 10.04; p = 0.0123). The mean increase in blood pressure variables in the ibuprofen group was significantly different compared with the mean increase in the variables in the placebo group after 3 weeks of treatment: supine systolic blood pressure (7.1 mm Hg compared with -4.5 mm Hg; 95% CI for the difference in means, 2.5 to 20.6; p = 0.0133); supine diastolic pressure (6.4 mm Hg compared with 0.0; 95% CI for difference in means, 0.87 to 12.4; p = 0.0250); supine mean arterial pressure (6.6 mm Hg compared with -1.5; 95% CI for difference in means, 2.0 to 14.2; p = 0.0110); sitting systolic pressure (6.8 mm Hg compared with -3.7; 95% CI for difference in means, 2.0 to 19.0; p = 0.0169); sitting diastolic pressure (5.3 mm Hg compared with -1.1; 95% CI for difference in means, 0.76 to 12.1; p = 0.0273); and sitting mean arterial pressure (5.8 mm Hg compared with -2.0; 95% CI for difference in means, 1.5 to 14.1; p = 0.0169).(ABSTRACT TRUNCATED AT 400 WORDS)
评估布洛芬对正在接受抗高血压药物治疗患者血压控制的影响。
在3周治疗期内,将布洛芬与对乙酰氨基酚及安慰剂进行随机、双盲、安慰剂对照、平行试验。
一所大学医院的普通内科门诊。
纳入45例经至少两种抗高血压药物治疗血压得到控制的原发性高血压患者。其中,41例完成研究;布洛芬组15例患者中有3例因药物胶囊破裂而中断治疗,安慰剂组14例患者中有1例在随机分组后因不稳定型心绞痛中断治疗。对乙酰氨基酚组的15例患者均完成研究。
继续之前所有的抗高血压治疗方案。在3周治疗期间,每8小时口服一次400毫克布洛芬;每8小时口服一次1克对乙酰氨基酚;或每8小时口服2粒安慰剂胶囊。
在布洛芬组,治疗3周后平均仰卧舒张压较基线的平均升高幅度显著(6.4毫米汞柱;95%置信区间[CI],1.05至11.75;p = 0.0239);仰卧平均动脉压(6.6毫米汞柱;95% CI,1.25至11.95;p = 0.0205);坐位平均动脉压(5.8毫米汞柱;95% CI,1.57至10.04;p = 0.0123)。治疗3周后,布洛芬组血压变量的平均升高幅度与安慰剂组变量的平均升高幅度相比有显著差异:仰卧收缩压(7.1毫米汞柱对比 -4.5毫米汞柱;均值差异的95% CI,2.5至20.6;p = 0.0133);仰卧舒张压(6.4毫米汞柱对比0.0;均值差异的95% CI,0.87至12.4;p = 0.0250);仰卧平均动脉压(6.6毫米汞柱对比 -1.5;均值差异的95% CI,2.0至14.2;p = 0.0110);坐位收缩压(6.8毫米汞柱对比 -3.7;均值差异的95% CI,2.0至19.0;p = 0.0169);坐位舒张压(5.3毫米汞柱对比 -1.1;均值差异的95% CI,0.76至12.1;p = 0.0273);坐位平均动脉压(5.8毫米汞柱对比 -2.0;均值差异的95% CI,1.5至14.1;p = 0.0169)。(摘要截断于400字)